Leadership: Page 3
-
Permission granted by AstraZeneca
Q&AAZ oncology chief says AI can help solve cancer’s ‘ZIP code lottery’ as health disparities persist
Partnerships have been key to building the company’s AI capabilities and patient-focused R&D, said AstraZeneca’s head of U.S. oncology.
By Michael Gibney • May 8, 2024 -
Permission granted by Vertex
ProfileNow a biopharma powerhouse, Vertex’s R&D bedrock could deliver tomorrow’s blockbusters
From its landmark CRISPR approval to its potential breakthrough drug for pain, Vertex’s development approach, led by chief scientific officer Dr. David Altshuler, is paying off.
By Michael Gibney • April 30, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineCommercialization, marketing and social media
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
By PharmaVoice staff -
Courtesy of Alltrna
Q&AHow a biotech exec is leveraging Big Pharma lessons to advance tRNA
Michelle Werner shares how the lessons from her resume — and personal experience — are driving her work with novel therapeutics.
By Amy Baxter • April 29, 2024 -
Permission granted by Biogen
Biogen: Don’t expect any big acquisitions this year
While the company is eager to diversify, CEO Chris Viehbacher said that in the near-term any dealmaking would likely focus on collaborations and early-stage assets.
By Jacob Bell • April 24, 2024 -
Permission granted by eClinical Solutions
Q&AHow pharma’s surging M&A is impacting the industry’s tech sector
As dealmaking in biopharma picks up, the CEO of eClinical Solutions sees an opportunity for clinical software companies to make acquisitions easier to close.
By Michael Gibney • April 11, 2024 -
Stock via Getty Images
Women want to participate in clinical trials. Lack of flexibility is still a problem.
Underrepresentation of women in clinical trials affects the resulting drugs that are available down the line, but even small changes can fuel participation.
By Kelly Bilodeau • April 8, 2024 -
Permission granted by Avenga
Sponsored by AvengaUnlocking growth: How GenAI can help pharma companies convert new clients
GenAI is profoundly reshaping various facets of the pharmaceutical industry. Projections indicate that the global GenAI market in pharma will soar to $2258.1 million by 2032.
By Olena Domanska, Data Science Engineering Manager at Avenga • April 8, 2024 -
Permission granted by Verastem
Q&A // First 90 DaysWith an ovarian KRAS combo ready for review, Verastem’s CEO is poised for the transition
As its FDA filing approaches, Verastem Oncology CEO Daniel Paterson wants to go from “The Little Engine That Could” to a major oncology player.
By Michael Gibney • April 4, 2024 -
Permission granted by EMD Serono
Q&ATo advance women’s leadership, an effort ‘has to be purposeful,’ says EMD Serono exec
Gender diversity in leadership “doesn’t just happen,” — it requires institutional change, from investing in women’s startups to providing more generous family leave.
By Alexandra Pecci • April 1, 2024 -
Permission granted by Cardior
‘The heart is back,’ says Cardior CEO — Novo’s $1B+ deal rejuvenates a stale field
Novo Nordisk’s acquisition of Cardior Pharmaceuticals is a bet on new approaches to cardiovascular disease, says Cardior CEO Claudia Ulbrich.
By Michael Gibney • March 28, 2024 -
Permission granted by Art Krieg
Biotech veteran Art Krieg postpones retirement to build an unorthodox drug startup
With Zola Therapeutics, Krieg plans to design and sell a series of cancer immunotherapies without the help of outside investors, he told BioPharma Dive.
By Ben Fidler • March 28, 2024 -
Permission granted by Portal Bio
Q&ASQZ, Portal founder Armon Sharei on starting over in biotech
After his first biotech startup was sold off in parts, Sharei is applying the lessons he’s learned to a new company with a different business model.
By Gwendolyn Wu • March 26, 2024 -
Permission granted by Boehringer Ingelheim
Q&AWhy a pharmacist was tapped to spearhead ‘patient excellence’ at Boehringer Ingelheim
Deborah Reardon is leading a new pillar that asks, “Are we looking at this from a patient lens and not from a Boehringer lens?”
By Alexandra Pecci • March 25, 2024 -
Permission granted by Gates MRI
ProfileThe pharma ‘fixer’ now helping Gates MRI’s tuberculosis battle
After getting her start as a nurse, Debra Weiss worked her way up the corporate ladder and is now COO of Gates MRI, which just launched its first phase 3 trial for tuberculosis.
By Alexandra Pecci • March 22, 2024 -
Getty Images via Getty Images
As investors ‘lose trust’ in pharma’s business model, focused M&A strategies can help
A rebound in M&A seems to be on the docket, but analysts are warning companies to be intentional about where they go with it.
By Michael Gibney • March 19, 2024 -
Kevin Dietsch via Getty Images
5 Big Pharma CEOs who saw major pay bumps in 2023
Pharma’s recent wins have led to pay windfalls for several company leaders.
By Amy Baxter • March 18, 2024 -
Permission granted by Aily Labs
Ex-Novartis exec sets out to create ‘Apple of AI’
Aily Labs’ tech makes predictive business decisions for life science companies and comes from a need its founder witnessed in Big Pharma.
By Kelly Bilodeau • March 18, 2024 -
Stock via Getty Images
The silver lining around Lilly’s Alzheimer’s delay could be a future with better drugs
Although a regulatory delay for Eli Lilly’s donanemab in Alzheimer’s disease is a competitive setback, researchers have their eye on better drug development as a result.
By Michael Gibney • March 12, 2024 -
Permission granted by Tarsus Pharmaceuticals
Q&AInto the unknown: Tarsus’ CEO on its launch strategies in a new disease category
The company scored a first-in-class nod for its eye med last year, which treats a common but frequently undiagnosed condition.
By Meagan Parrish • March 8, 2024 -
Permission granted by Amylyx Pharmaceuticals
Amylyx ALS drug fails crucial study, putting company’s future in doubt
The results have led Amylyx to pause promotion of Relyvrio and potentially pull it from the market in the coming weeks, a major blow to the company and ALS patients.
By Jacob Bell • Updated March 8, 2024 -
Permission granted by Natalie Ferguson/American Gene Technologies
ProfileHIV isn’t ‘solved,’ but a doctor who treated some of the first patients hopes to finally deliver a cure
From San Francisco in the 80s to a gene therapy prospect, Dr. Marcus Conant looks back on his long fight against the virus — and if the industry is close to ending the epidemic.
By Michael Gibney • March 5, 2024 -
iStock via Getty Images
Q&ABiogen partner NeuroSense seeks a role in the ALS revolution
Results from a mid-stage study for a new ALS drug have been strong, and NeuroSense is looking to join a small but sturdy wave of companies bringing new treatments to market.
By Michael Gibney • Feb. 29, 2024 -
Permission granted by Lindus Health
Can a top scientist and Moderna co-founder change the CRO game?
From his advisory board role at Lindus Health, Robert Langer is aiming to overcome challenges in the CRO market.
By Michael Gibney • Feb. 28, 2024 -
Stock via Getty Images
A pandemic-era staffing crunch in clinical trials is easing, but trouble spots remain
How research companies can shift strategies to attract and retain the staff that keeps trials humming along.
By Kelly Bilodeau • Feb. 28, 2024 -
ismagilov via Getty Images
BioMarin preaches patience amid slow sales for hemophilia gene therapy
The company earned only $3.5 million last year from its Roctavian treatment, far below the $50 million to $150 million range it had forecast eight months ago.
By Ben Fidler • Feb. 23, 2024
Previous
